Skip to main content
. 2024 Dec 5;22:325. doi: 10.1186/s12957-024-03610-3

Table 2.

Univariate survival analysis for patients with UUS

Clinical Characteristics n % mPFS (months) P value mOS (months) P value
Age (years) 0.508 0.448
 <50 10 34.5 14.43 52.9
 ≥50 19 65.5 17.73 27.4
BMI (kg/m2) 0.844 0.349
 <24 15 51.7 12.8 22.2
 ≥24 14 48.3 15.53 28.2
Tumor size (cm) 0.121 0.324
 <10 15 51.7 25.87 35.03
 ≥10 14 48.3 6.47 20.43
FIGO Stage 0.003 0.087
 I-II 22 75.9 17.73 35.03
 III-IV 7 24.1 5.97 6.67
Lymphadenectomy 0.010 0.201
 Yes 17 58.6 25.23 52.9
 No 12 41.4 9.7 20.4
Omentectomy 0.016 0.078
 Yes 8 27.6 NR 99.9
 No 21 72.4 11.97 21.8
Myometrial invasion 0.090 0.671
 <1/2 11 37.9 25.87 35
 ≥1/2 16 55.2 11.4 20.4
 NA 2 6.9
Cervical involvement 0.588 0.353
 Yes 4 13.8 6.467 6.47
 No 23 79.3 17.07 35
 NA 2 6.9
Adjuvant chemotherapy 0.220 0.062
 Yes 23 79.3 17.73 35.03
 No 6 20.7 14.43 14.43

Abbreviation: UUS, undifferentiated uterine sarcomas; mPFS, median progression free survival; mOS, median overall survival; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; NA, not available